

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kenneth N. Raymond *et al.*Application No. **10/585,178**Intl Filing Date: **October 3, 2008**For: **AROMATIC TRIAMIDE-
LANTHANIDE COMPLEXES**Conf. No. **2127**Art Unit: **1797**Examiner: **To be determined**Docket No.: **061818-02-5009-US***Certificate of Transmission (37 C.F.R. § 1.8)**I hereby certify that this correspondence is being transmitted to the
U.S. Patent and Trademark Office via the Office electronic filing
system in accordance with § 1.6(a)(4) on July 9, 2010**Jennifer C. Black**Jennifer C. Black*Mail Stop AMENDMENT
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This Supplemental Information Disclosure Statement is hereby submitted in accordance with 37 C.F.R. 1.98 and pursuant to Applicant's continuing duty under 37 C.F.R. 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention. The Examiner's attention is directed to the reference(s) cited on the accompanying substitute for form PTO-1449A/PTO. Except for U.S. Patents and U.S. Patent Application Publications, *see* 37 C.F.R. § 1.98(a)(2)(i), copies of the cited references are enclosed, unless otherwise noted below. It is further understood that the Examiner will also consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. M.P.E.P. § 609.06 (A)(2).

Applicant makes no representation that a search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material to patentability. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 11 O.G. 13-25, at 25.

In accordance with M.P.E.P. 2001.06(b) and in view of *McKesson Information Solutions v. Bridge Medical* (Fed. Cir. 2007), Applicants wish to inform/remind the Examiner that this application is related to the following U.S. Patent Applications: U.S. Patent Application No. 11/839,509 filed August 15, 2007; U.S. Patent Application No. 12/020,470 filed January 25, 2008; U.S. Patent Application No. 12/202,367 filed September 1, 2008; U.S. Patent Application No. 12/611,035 filed November 2, 2009; and U.S. Patent Application No. 12/521,910 filed March 15, 2010.

The Examiner is encouraged to review the art made of record, any Office Action, and any Notice of Allowance in the above-mentioned related application. Applicants assume that due to the ease of review on PAIR by the Examiner, Applicant need not submit copies of the individual Office Actions and/or Notices of Allowance.

The identification of the above related application is not to be construed as a waiver of secrecy as to the application now or upon issuance of the present application as a patent.

This Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. 37 C.F.R. § 1.97(b). No fee is required.

The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 50-0310 (Order No. 061818-02-5009-US).

Respectfully submitted,

Date: July 9, 2010

By: Tuan N. Nguyen
Tuan N. Nguyen, Reg. No. 62,971

MORGAN LEWIS & BOCKIUS LLP
One Market, Spear Street Tower
San Francisco, California 94105
Tel: 415.442.1000
Fax: 415.442.1001